Method of treating movement disorders by brain infusion

• US 5,832,932 A
• Filed: 04/30/1997
• Issued: 11/10/1998
• Est. Priority Date: 04/30/1996
• Status: Expired due to Term

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Rise, Mark T., Elsberry, Dennis D., Ward, Scott R.
• Primary Examiner(s): Jones, Mary Beth
• Assistant Examiner(s): CAMPEN, KELLY SCAGGS
• Application Number:
  US08/846,807
• Time in Patent Office: 559 Days
• Field of Search: 128/898, 604/4, 604/890.1, 604/891.1, 604/93, 604/49, 604/50, 604/52, 604/53, 604/153, 604/246, 604/892.11, 604/67, 604/5, 604/6, 623/12
• US Class Current: 128/898
• CPC Class Codes: A61M 2202/0464 Cerebrospinal fluid
• CPC Class Codes: A61M 2210/0693 Brain, cerebrum
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00

Abstract

The present invention is directed to techniques and apparatus for infusing drugs into the brain to treat movement disorders resulting in abnormal motor behavior. The invention employs an implantable pump and a catheter, the catheter having a proximal end coupled to the pump and a discharge portion for placement adjacent a predetermined infusion site in the brain for infusing therapeutic dosages of the one or more drugs into the brain. The pump is operated to discharge a predetermined dosage of the one or more drugs through the discharge portion of the catheter into the infusion site. A sensor may be used in combination with the implantable pump and catheter, whereby the sensor generates a signal relating to the extent of the abnormal motor behavior. The therapeutic dosage is regulated so that the dosage is adjusted in response to an increase in the abnormal behavior to decrease the abnormal motor behavior.

Claims

1. A method of using one or more drugs to treat a movement disorder resulting in abnormal motor behavior by means of an implantable pump and a catheter having a proximal end coupled to said pump and a discharge portion for infusing therapeutic dosages of said one or more drugs comprising the steps of:

surgically implanting said catheter in the brain so that the discharge portion lies adjacent to a predetermined infusion site in the brain wherein said predetermined infusion site is selected from the group consisting of ventrolateral thalamus (Thal), internal segment of globus pallidus (GPi), substantia nigra pars reticulata (SNr), subthalamic nucleus (STN), external segment of globus pallidus (GPe), striatum, and neostriatum; and

operating said pump to discharge a predetermined dosage of said one or more drugs through said discharge portion of said catheter into said infusion site, whereby said abnormal motor behavior is therapeutically treated.

2. A method, as claimed in claim 1, wherein said movement disorder is a hyperkinetic disorder;

and

wherein said drugs are selected to reduce thalamic output.

3. A method, as claimed in claim 2, wherein said hyperkinetic disorder comprises Huntington'"'"'s disease, amyotrophic lateral sclerosis, ballism, or dystonia.

4. A method, as claimed in claim 2, wherein said one or more drugs decrease excitement of the thalamus or increase inhibition of the thalamus.

5. A method, as claimed in claim 4, wherein said one or more drugs decrease inhibition or increase excitation of said internal segment of globus pallidus (GPi) or said substantia nigra pars reticulata (SNr) that inhibit thalamic output.

6. A method, as claimed in claim 5, wherein said one or more drugs are selected from the group consisting of a glutamate antagonist, a glutamate agonist, a γ

-aminobutyric acid (GABA) antagonist, a γ

-aminobutyric acid (GABA) agonist, a dopamine (DA) antagonist and a dopamine (DA) agonist.

7. A method, as claimed in claim 1, wherein said movement disorder is a hypokinetic disorder;

and

wherein said drugs are selected to increase thalamic output.

8. A method, as claimed in claim 7, wherein said hypokinetic disorder comprises Parkinson'"'"'s disease.

9. A method, as claimed in claim 7, wherein said one or more drugs increase excitement of the thalamus or decrease inhibition of the thalamus.

10. A method, as claimed in claim 9, wherein said one or more drugs increase inhibition or decrease excitation of said internal segment of globus pallidus (GPi) or said substantia nigra pars reticulata (SNr) that inhibit thalamic output.

11. A method, as claimed in claim 10, wherein said one or more drugs are selected from the group consisting of a glutamate antagonist, a glutamate agonist, a γ

-aminobutyric acid (GABA) antagonist, a γ

-aminobutyric acid (GABA) agonist, a dopamine (DA) antagonist and a dopamine (DA) agonist.

12. A method of using one or more drugs to treat a movement disorder resulting in abnormal motor behavior by means of an implantable pump and a catheter having a proximal end coupled to said pump and a discharge portion for infusing therapeutic dosages of at least one drug comprising the steps of:

surgically implanting said catheter in the brain so that the discharge portion lies adjacent to a predetermined infusion site in the brain; and

implanting an implantable sensor for generating a signal for detecting the extent of abnormal motor behavior and for signaling said pump to discharge a dosage of said at least one drug through said discharge portion of said catheter into said infusion site, whereby said abnormal motor behavior is therapeutically treated.

13. A method, as claimed in claim 12, wherein the step of implanting including the step of positioning said sensor to sense motion behavior of a portion of a body.

14. A method, as claimed in claim 12, wherein the step of implanting including the step of positioning said sensor to sense abnormal movement behavior of a portion of a body.

15. A method, as claimed in claim 12, wherein the step of implanting including the step of positioning said sensor to sense gravity direction.

16. A method, as claimed in claim 12, wherein the step of implanting including the step of positioning said sensor to sense motion relative to an object.

17. A method, as claimed in claim 12, wherein the step of implanting including the step of positioning said sensor to sense muscle EMG.

18. A method, as claimed in claim 12, wherein the step of implanting including the step of positioning said sensor to sense brain EEG.

19. A method, as claimed in claim 12, wherein the step of implanting including the step of positioning said sensor to sense nerve compound action potentials.

20. A method, as claimed in claim 12, wherein the step of implanting including the step of positioning said sensor to sense posture of a patient.

21. A method, as claimed in claim 12, wherein the step of implanting including the step of positioning said sensor to sense nerve cell activity.

22. A method, as claimed in claim 12, wherein the step of implanting including the step of positioning said sensor to sense electrical activity in a thalamus.

23. A method, as claimed in claim 12, further comprising the step of implanting said pump to discharge a dosage of said at least one drug.

24. A method, as claimed in claim 12, further comprising the step of implanting a drug administration device containing said at least one drug.

25. A method, as claimed in claim 12, further comprising the step of implanting a drug administration device containing said at least one drug and a microprocessor for regulating said pump to discharge a dosage of said at least one drug.